Monthly
US$200
Billed every month
Lanthanum Carbonate Chewable Tablets(碳酸镧咀嚼片)
Companies, stages and changes, with each record available on this page.
No changes recorded by this site in the last 90 days
Complete CDE snapshot: 2026/11/10 07:27
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders14View records ↓
Under-review filings2View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers15View records ↓
API companies with A status20View records ↓
Chemical-drug catalogue
Loaded records: 14 holders; 1 in the quality-and-efficacy consistency-evaluation category, and 11 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 浙江中同药业有限公司 | 浙江中同药业有限公司 | 国药准字H20263491 | 2026/03/03 | 500mg(以镧计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州安元生物医药科技有限公司 | 苏州爱美津制药有限公司 | 国药准字H20253619 | 2025/03/11 | 500mg（以镧计） | Not stated by source | CDE |
| Natco Pharma Limited | Natco Pharma Limited | 国药准字HJ20240159 | 2024/12/06 | 500mg（以镧计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Natco Pharma Limited | Natco Pharma Limited | 国药准字HJ20240160 | 2024/12/06 | 1000mg（以镧计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 青岛百洋制药有限公司 | 青岛百洋制药有限公司 | 国药准字H20244877 | 2024/09/10 | 0.5g（以镧计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 温州海鹤药业有限公司 | 浙江昂利康制药股份有限公司 | 国药准字H20244505 | 2024/07/30 | 0.5g（以镧计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东齐都药业有限公司 | 山东齐都药业有限公司 | 国药准字H20244466 | 2024/07/16 | 500mg（以镧计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西施美药业股份有限公司 | 江西施美药业股份有限公司 | 国药准字H20243904 | 2024/06/04 | 500mg（以镧计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 仁合益康集团有限公司 | 河北仁合益康药业有限公司 | 国药准字H20243738 | 2024/05/21 | 500mg（以镧计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 仁合益康集团有限公司 | 河北仁合益康药业有限公司 | 国药准字H20243739 | 2024/05/21 | 750mg（以镧计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Mylan Laboratories Limited | Mylan Laboratories Limited | 国药准字HJ20230116 | 2023/10/18 | 500mg（以镧计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 沈阳福宁药业有限公司 | 沈阳福宁药业有限公司 | 国药准字H20233126 | 2023/02/07 | 500mg（以镧计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 沈阳福宁药业有限公司 | 沈阳福宁药业有限公司 | 国药准字H20233125 | 2023/02/07 | 250mg（以镧计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20223690 | 2022/09/20 | 500mg（以镧计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南明瑞制药有限公司 | 湖南明瑞制药有限公司 | 国药准字H20203039 | 2022/03/15 | 500mg(以镧计) | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 四川自豪时代药业有限公司 | 四川自豪时代药业有限公司 | 国药准字H20213953 | 2021/12/27 | 0.5g(以镧计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Shire Pharmaceuticals Ireland Limited | Hamol Limited | H20171351;H20171352 | 2012/02/10 | 500mg | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 15 distinct approval numbers and 14 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 沈阳华泰药物研究有限公司 | 国药准字H20233126 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010101287 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20223690 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010101606 | NHSA |
| 青岛百洋制药有限公司 | 国药准字H20244877 | 0.5g(以镧计) | Category B (乙) | XV03AET152A005010104023 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20244466 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010104145 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20244505 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010104586 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20203039 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010105001 | NHSA |
| HAMOL LIMITED | H20171351 | 500mg | Category B (乙) | XV03AET152A005010179538 | NHSA |
| 青神虹豪制药有限公司 | 国药准字H20213953 | 0.5g(以镧计) | Category B (乙) | XV03AET152A005010181555 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243738 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010183033 | NHSA |
| 杭州安元生物医药科技有限公司 | 国药准字H20253619 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010183777 | NHSA |
| Natco Pharma Limited | 国药准字HJ20240159 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010184131 | NHSA |
| 浙江中同药业有限公司 | 国药准字H20263491 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010184243 | NHSA |
| 沈阳华泰药物研究有限公司 | 国药准字H20233126 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010201287 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20223690 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010201606 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20244505 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010204586 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20203039 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010205001 | NHSA |
| Takeda Pharmaceuticals International AG Ireland Branch | 国药准字HJ20171351 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010279538 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243738 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010283033 | NHSA |
| 杭州安元生物医药科技有限公司 | 国药准字H20253619 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010283777 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20223690 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010301606 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20244505 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010304586 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20203039 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010305001 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243738 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010383033 | NHSA |
| 杭州安元生物医药科技有限公司 | 国药准字H20253619 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010383777 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243738 | 500mg(以镧计) | Category B (乙) | XV03AET152A005010483033 | NHSA |
| 沈阳福宁药业有限公司 | 国药准字H20233125 | 250mg(以镧计) | Category B (乙) | XV03AET152A005020101287 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243739 | 750mg(以镧计) | Category B (乙) | XV03AET152A005020183033 | NHSA |
| 沈阳福宁药业有限公司 | 国药准字H20233125 | 250mg(以镧计) | Category B (乙) | XV03AET152A005020201287 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243739 | 750mg(以镧计) | Category B (乙) | XV03AET152A005020283033 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20243739 | 750mg(以镧计) | Category B (乙) | XV03AET152A005020383033 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 2 filings and 2 distinct first applicants.
Generic 2
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
API registrations
Non-component matches: 20 companies with A status and 5 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 碳酸镧 | 山东科新药业有限公司 | Y20260000124 | I | Exact ingredient | 2026/02/13 | CDE |
| 碳酸镧 | 日照正济药业有限公司 | Y20250000998 | I | Exact ingredient | 2025/10/16 | CDE |
| 碳酸镧 | 内蒙古京东药业有限公司 | Y20250000378 | A | Exact ingredient | 2026/10/12 | CDE |
| 碳酸镧 | 珠海润都制药股份有限公司 | Y20240001423 | A | Exact ingredient | 2026/07/20 | CDE |
| 碳酸镧 | 卡文迪许（泰州）药业有限公司 | Y20240000789 | A | Exact ingredient | 2025/12/08 | CDE |
| 碳酸镧 | 浙江仟源海力生制药有限公司 | Y20240000582 | A | Exact ingredient | 2026/01/30 | CDE |
| 碳酸镧 | 康臣药业（内蒙古）有限责任公司 | Y20240000103 | A | Exact ingredient | 2025/11/25 | CDE |
| 碳酸镧 | 河北华晨药业集团有限公司 | Y20240000166 | A | Exact ingredient | 2025/08/14 | CDE |
| 碳酸镧 | 福建南方制药股份有限公司 | Y20230001019 | A | Exact ingredient | 2026/06/02 | CDE |
| 碳酸镧 | 浙江国邦药业有限公司 | Y20220001199 | A | Exact ingredient | 2026/07/09 | CDE |
| 碳酸镧 | 苏州正济药业有限公司 | Y20220000535 | A | Exact ingredient | 2025/03/18 | CDE |
| 碳酸镧 | 山东齐都药业有限公司 | Y20220000985 | A | Exact ingredient | 2025/04/29 | CDE |
| 碳酸镧 | 浙江昂利康制药股份有限公司 | Y20220001024 | A | Exact ingredient | 2024/06/28 | CDE |
| 碳酸镧 | 湖南华纳大药厂手性药物有限公司 | Y20220000933 | A | Exact ingredient | 2026/01/17 | CDE |
| 碳酸镧 | 沈阳福宁药业有限公司 | Y20210001310 | A | Exact ingredient | 2024/01/17 | CDE |
| 碳酸镧 | 山东朗诺制药有限公司 | Y20220000402 | A | Exact ingredient | 2024/11/09 | CDE |
| 碳酸镧 | 河北安健成益医药科技有限公司 | Y20220000312 | A | Exact ingredient | 2025/07/29 | CDE |
| 碳酸镧 | SYMED LABS LIMITED | Y20220000271 | I | Exact ingredient | 2024/09/27 | CDE |
| 碳酸镧 | Matrix Pharmacorp Private Limited | Y20220000002 | A | Exact ingredient | 2026/03/05 | CDE |
| 碳酸镧 | 四川自豪时代药业有限公司 | Y20200001552 | A | Exact ingredient | 2026/07/27 | CDE |
| 碳酸镧 | 江苏普润生物医药有限公司 | Y20200001500 | A | Exact ingredient | 2024/11/19 | CDE |
| 碳酸镧 | Natco Pharma Limited | Y20200001143 | A | Exact ingredient | 2025/12/25 | CDE |
| 碳酸镧 | Solara Active Pharma Sciences Limited | Y20200000776 | I | Exact ingredient | 2022/10/14 | CDE |
| 碳酸镧 | 成都新越医药有限公司 | Y20180001526 | I | Exact ingredient | 2019/02/15 | CDE |
| 碳酸镧 | 湖南明瑞制药股份有限公司 | Y20170000984 | A | Exact ingredient | 2024/03/23 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Lanthanum Carbonate Chewable Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy